Psychiatric symptoms screening in the early stages of Parkinson's disease
- PMID: 21691730
- DOI: 10.1007/s00415-011-6140-8
Psychiatric symptoms screening in the early stages of Parkinson's disease
Abstract
Psychiatric complaints are common in Parkinson's disease (PD), and have a significant influence in disease outcome and quality of life. Little attention has been paid to psychiatric symptoms at early stage disease. We aimed to screen a population of early stage PD patients for psychiatric symptoms and to study the relation with motor and cognitive function. Thirty-six early stage PD patients underwent motor [Hoehn and Yahr (HY), Unified Parkinson's Disease Rating Scale] and cognitive [Frontal Assessment Battery, Mini-Mental State Examination (MMSE)] assessment as well as general psychiatric [Symptom Check-List 90 (SCL-90-R)] and psychosis [Brief Psychiatric Rating Scale (BPRS)] screening. Relation between psychiatric domains scores was studied with principal component analysis. Relation between psychiatric, disease related, cognitive and motor function was assessed with bivariate correlation (Pearson). SCL-90-R scores were higher for somatization (significant scores in 66.7% of patients), depression (36.1%), anxiety (27%) and obsessive-compulsive symptoms (OCS) (52.8%). Scores were highly correlated, except for psychosis and phobia. Depression and anxiety were negatively correlated to MMSE score and dopaminergic doses, respectively. BPRS scores were higher for somatic concern, depression, anxiety and hallucinations. There was segregation between depression, anxiety, hallucinations, other positive psychotic symptoms and negative psychotic symptoms. Depression was related to MMSE score. We found a high prevalence of psychiatric complaints in PD patients, mostly related to depression, anxiety, somatization and OCS. Hallucinations were also frequent, but not associated to cognitive function or dopaminergic doses, suggesting a different physiopathological background.
Similar articles
-
Screening for anxiety symptoms in Parkinson disease: a cross-sectional study.J Geriatr Psychiatry Neurol. 2013 Mar;26(1):34-40. doi: 10.1177/0891988713476368. Epub 2013 Feb 13. J Geriatr Psychiatry Neurol. 2013. PMID: 23407399
-
Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD).J Neurol. 2008 Feb;255(2):255-64. doi: 10.1007/s00415-008-0720-2. Epub 2008 Jan 22. J Neurol. 2008. PMID: 18204803
-
Cognitive and motor function in patients with Parkinson's disease with and without depression.Clin Neuropharmacol. 2000 Nov-Dec;23(6):331-4. doi: 10.1097/00002826-200011000-00006. Clin Neuropharmacol. 2000. PMID: 11575867 Clinical Trial.
-
Psychosis, apathy, depression and anxiety in Parkinson's disease.Neurobiol Dis. 2012 Jun;46(3):581-9. doi: 10.1016/j.nbd.2011.12.041. Epub 2012 Jan 3. Neurobiol Dis. 2012. PMID: 22245219 Review.
-
Psychiatric aspects of Parkinson's disease--an update.J Neurol. 2004 Jul;251(7):795-804. doi: 10.1007/s00415-004-0483-3. J Neurol. 2004. PMID: 15258780 Review.
Cited by
-
Global research trends and hotspots in Parkinson's disease psychosis: a 25-year bibliometric and visual analysis.Front Aging Neurosci. 2024 Nov 22;16:1480234. doi: 10.3389/fnagi.2024.1480234. eCollection 2024. Front Aging Neurosci. 2024. PMID: 39649718 Free PMC article.
-
Time to add two new disorders to neuropsychiatric aspects of Parkinson's disease.Clin Park Relat Disord. 2025 Jun 15;13:100358. doi: 10.1016/j.prdoa.2025.100358. eCollection 2025. Clin Park Relat Disord. 2025. PMID: 40607315 Free PMC article. Review.
-
Neurodegeneration in Parkinson's disease: interactions of oxidative stress, tryptophan catabolites and depression with mitochondria and sirtuins.Mol Neurobiol. 2014 Apr;49(2):771-83. doi: 10.1007/s12035-013-8554-z. Epub 2013 Oct 2. Mol Neurobiol. 2014. PMID: 24085563 Review.
-
Non-Motor symptoms in Portuguese Parkinson's Disease patients: correlation and impact on Quality of Life and Activities of Daily Living.Sci Rep. 2016 Aug 30;6:32267. doi: 10.1038/srep32267. Sci Rep. 2016. PMID: 27573215 Free PMC article.
-
Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease.Am J Neurodegener Dis. 2016 Mar 1;5(1):29-51. eCollection 2016. Am J Neurodegener Dis. 2016. PMID: 27073741 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous